Stifel Maintains Buy on Macrogenics, Raises Price Target to $29
Portfolio Pulse from Benzinga Newsdesk
Stifel analyst Stephen Willey maintains a Buy rating on Macrogenics (NASDAQ:MGNX) and raises the price target from $17 to $29, indicating a positive outlook on the company's stock.
March 08, 2024 | 3:42 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Stifel analyst Stephen Willey maintains a Buy rating on Macrogenics and raises the price target from $17 to $29.
The increase in price target by a reputable analyst suggests a strong confidence in Macrogenics' future performance. This endorsement is likely to positively influence investor sentiment and potentially drive up the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100